CC
KYTX icon

Caxton Corporation’s Kyverna Therapeutics KYTX Stock Holding History

Caxton Corporation’s Portfolio KYTX Stock Details KYTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$162K Hold
18,773
– – 4.03% 3
2025
Q4 		$176K Sell
18,773
-4,208
-18% -$31.2K 4.12% 5
2025
Q3 		$138K Hold
22,981
– – 0.6% 8
2025
Q2 		$70.6K Hold
22,981
– – 0.72% 8
2025
Q1 		$44.4K Hold
22,981
– – 0.87% 8
2024
Q4 		$86K Hold
22,981
– – 0.52% 9
2024
Q3 		$112K Hold
22,981
– – 0.47% 9
2024
Q2 		$172K Buy
22,981
+7,135
+45% +$109K 0.87% 8
2024
Q1 		$394K Buy
+15,846
New +$442K 2.24% 5

Other funds holding KYTX

GGI
GordonMD Global Investments Beverely Hills, California $144M AUM
GS
Gilead Sciences Foster City, California $2.12B AUM 143.53% 1-Year Est. Return
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return
ACM
AIGH Capital Management Baltimore, Maryland $733M AUM 327.32% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
IHG
Insight Holdings Group New York $1.42B AUM 41.03% 1-Year Est. Return

Caxton Corporation's KYTX Position: Q1 2026 in Review

Caxton Corporation held its Kyverna Therapeutics (KYTX) position steady in Q1 2026 at 18,773 shares worth $162K. The position accounts for 4.03% of the portfolio, ranked #3.

Caxton Corporation first reported a position in KYTX in Q1 2024 and has held it in 9 quarters since. The position peaked at $394K in Q1 2024. 111 funds tracked by Wall St. Rank hold KYTX as of Q1 2026.

  • Caxton Corporation held 18,773 shares of Kyverna Therapeutics worth $162K as of Q1 2026.
  • Caxton Corporation left its Kyverna Therapeutics share count unchanged in Q1 2026.
  • Kyverna Therapeutics made up 4.03% of Caxton Corporation's portfolio in Q1 2026, its #3 holding.
  • Caxton Corporation first reported a position in Kyverna Therapeutics in Q1 2024 and has held it in 9 quarters since.
  • Caxton Corporation's Kyverna Therapeutics position peaked at $394K in Q1 2024.
  • 111 funds tracked by Wall St. Rank held Kyverna Therapeutics as of Q1 2026.

Based on Caxton Corporation's 13F filing for Q1 2026, filed 14 May 2026.